移动血管内治疗在多院急性处理破裂椎动脉夹层动脉瘤
该回顾性研究纳入2000至2018年间在旗舰中心或五家附属医院接受血管内治疗的98例破裂椎动脉夹层动脉瘤患者,采用神经血管内 surgeons 从旗舰中心直接前往附属医院实施治疗的移动血管内策略。所有动脉瘤均通过内部填塞成功治愈,62.2%患者获得良好预后,总死亡率为18.4%,治疗相关死亡率为0%,治疗相关并发症率为16%,旗舰中心与附属医院治疗的患者在临床和影像学结局上无差异。
要点
- 移动血管内治疗策略在超急性期治疗破裂椎动脉夹层动脉瘤中可行。
- 所有动脉瘤均通过内部填塞成功治愈。
- 附属医院治疗并非不良预后的预测因素。
核心结论
- 移动血管内治疗在特定情况下可有效且安全地用于破裂椎动脉夹层动脉瘤的超急性期治疗。
研究设计与样本
- 回顾性评估2000至2018年间在机构或五家附属医院连续接受血管内治疗的98例破裂椎动脉夹层动脉瘤患者。
- 神经血管内 surgeons 从旗舰中心直接前往附属医院为患者实施治疗。
主要发现
- 所有动脉瘤均通过内部填塞成功治愈。
- 61例患者(62.2%)获得良好预后,尽管53例患者(54.1%)表现为严重蛛网膜下腔出血。
- 总体死亡率为18.4%(18/98),治疗相关死亡率为0%,治疗相关并发症率为16%(16/98)。
- 旗舰中心与附属医院治疗的患者在临床和影像学结局上无差异。
- 多变量分析中,附属医院治疗并非不良预后的预测因素,高龄(≥60岁)与良好预后负相关。
临床怎么用
- 对于破裂椎动脉夹层动脉瘤,可考虑采用移动血管内治疗策略在附属医院实施早期治疗。
- 高龄(≥60岁)患者预后可能较差,需综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The patients with ruptured vertebral artery dissecting aneurysm (rVADA) should be treated as early as possible because VADA carries extremely high risk of rebleeding in the acute phase. We have established a mobile endovascular strategy for the patients with rVADA between our flagship center and its affiliated local hospitals. We introduced and reviewed our mobile endovascular therapy in this study. METHODS: We retrospectively evaluated 98 consecutive patients who underwent endovascular surgery for rVADA from 2000 to 2018 at our institution or five affiliated hospitals. When each patient was initially transported to the local affiliated hospitals, neuroendovascular surgeons traveled directly to the affiliated hospital from the flagship center in order to treat the patient there. Clinical outcomes using modified Rankin Scale at 6 months after treatment, radiological results, and procedure-related complications were reviewed to justify our mobile endovascular strategy. RESULTS: All aneurysms were cured successfully by internal trapping. Favorable outcome was achieved in 61 patients (62.2%) even though 53 patients (54.1%) had presented with severe subarachnoid hemorrhage. Overall mortality rate, treatment-related mortality rate, and treatment related complication rate were 18.4% (18/98), 0%, and 16% (16/98), respectively. There were no differences in clinical and radiological outcomes between the patients treated in the flagship center and those who treated in the affiliated hospitals. Treatment in the affiliated hospital was not a predictive factor of unfavorable outcome in our multivariate analysis, and elderly age (≥ 60) was negatively associated with favorable outcome. CONCLUSIONS: Our results prove the efficacy and safety of mobile endovascular therapy for the treatment of rVADA in the ultra-acute stage. Mobile endovascular therapy may work well in the acute treatment of rVADAs in the certain circumstance.
引用
- Kidani N, Sugiu K, Terasaka K, et al. Mobile endovascular therapy for acute treatment of ruptured vertebral artery dissecting aneurysm in multiple hospitals. Acta Neurochir (Wien). 2021. PMID: 34146152. doi:10.1007/s00701-021-04885-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。